Cited by 2,770Cancer Cells and MetastasisDrug Transport and Resistance MechanismsCancer Genomics and Diagnostics

The DOI matches its Crossref record; 183 of the 188 references it cites were found in a registry or an index.

A view on drug resistance in cancer

Open access

Vasan, Neil, Baselga, José, Hyman, David M.·2019·Nature

DOI 10.1038/s41586-019-1730-1PMC PMC8008476

Open this paper in CoChat — free account Open PDF

Abstract

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist approach to define and separate the key determinants of drug resistance, which include tumour burden and growth kinetics; tumour heterogeneity; physical barriers; the immune system and the microenvironment; undruggable cancer drivers; and the many consequences of applying therapeutic pressures. We propose four general solutions to drug resistance that are based on earlier detection of tumours permitting cancer interception; adaptive monitoring during therapy; the addition of novel drugs and improved pharmacological principles that result in deeper responses; and the identification of cancer cell dependencies by high-throughput synthetic lethality screens, integration of clinico-genomic data and computational modelling. These different approaches could eventually be synthesized for each tumour at any decision point and used to inform the choice of therapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-019-1730-1

Cites

183 of 183 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The Clonal Evolution of Tumor Cell Populations: Acquired genetic lability permits stepwise selection of variant sublines and underlies tumor progression.
Nowell, P. C. (1976) · Science · doi:10.1126/science.959840 · Cited by 6,471
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588

Show all 188 references

Research works printed but not linked: 1

Goldie, J. H. & Coldman, A. J. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat. Rep. 63, 1727–1733 (1979).

Sorted by citations

Items 601–700 of 1,001

Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review
Szulc, A., & Woźniak, M. (2024) · Cancers · doi:10.3390/cancers16081483 · Cited by 32
The role of SIRT1 in autophagy and drug resistance: unveiling new targets and potential biomarkers in cancer therapy
Tang, Y., Ju, W., Liu, Y., & Deng, Q. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1469830 · Cited by 30
Integrative spatial and genomic analysis of tumor heterogeneity with Tumoroscope
Shafighi, S. D., Geras, A., Jurzysta, B., Naeini, A. S., Filipiuk, I., Rączkowski, Ł., Toosi, H., Koperski, Ł., Thrane, K., Engblom, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53374-3 · Cited by 29
Recent Advances in 1,2,4‐Triazole‐Based Anticancer Agents: Structural Optimization, Mechanisms, and Therapeutic Potential (2022–2025)
Naeem, N., Mughal, E. U., Sadiq, A., Othman, G. A., & Shakoor, B. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70059 · Cited by 33
Activatable near-infrared organic photosensitizers for imaging-guided photodynamic therapy
Zhao, C., Du, T., Zhu, B., He, Z., Wang, H.-Y., & Liu, Y. (2025) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2025.216962 · Cited by 30
Antibacterial activities and antiproliferative assays over a tumor cells panel of a silver complex with 4-aminobenzoic acid: Studies in vitro of sustained release using bacterial cellulose membranes as support
Aquaroni, N. A. S., Nakahata, D. H., Lazarini, S. C., Resende, F. A., Cândido, A. L. P., Barud, H. D. S., Claro, A. M., de Carvalho, J. E., Ribeiro, C. M., Pavan, F. R., et al. (2020) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2020.111247 · Cited by 30
A review on RNAi therapy for NSCLC : Opportunities and challenges
KUMAR, V. K., Yadavilli, S., & Kannan, R. (2020) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1677 · Cited by 32
In-Cell Labeling and Mass Spectrometry for Systems-Level Structural Biology
Chavez, J. D., Wippel, H. H., Tang, X., Keller, A., & Bruce, J. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00223 · Cited by 29
A Nanotheranostic System Combining Lysosomal Cell Death and Nuclear Apoptosis Functions for Synergistic Cancer Therapy and Addressing Drug Resistance
Li, Y., Wu, Q., Li, D., Huang, J., Wen, H., Wu, Y., Wang, D., & Tang, B. Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202106091 · Cited by 29
Polymeric Nanoparticles for Mitochondria Targeting Mediated Robust Cancer Therapy
Sun, Y., Yang, Q., Xia, X., Li, X., Ruan, W., Zheng, M., Zou, Y., & Shi, B. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.755727 · Cited by 31
MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets
Marima, R. M., Francies, F. Z., Hull, R., Molefi, T., Oyomno, M., Khanyile, R., Mbatha, S. Z., Mabongo, M., Bates, D. O., & Dlamini, Z. (2021) · Biomedicines · doi:10.3390/biomedicines9121818 · Cited by 30
MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy
Wan, J.-L., Wang, B., Wu, M.-L., Li, J., Gong, R.-M., Song, L.-N., Zhang, H., Zhu, G., Chen, S.-P., Cai, J., et al. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215750 · Cited by 29
NAD/NAMPT and mTOR Pathways in Melanoma: Drivers of Drug Resistance and Prospective Therapeutic Targets
Indini, A., Fiorilla, I., Ponzone, L., Calautti, E., & Audrito, V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179985 · Cited by 31
Anti-breast cancer potential activity of Phaleria macrocarpa (Scheff.) Boerl. leaf extract through in silico studies
Christina, Y. I., Nafisah, W., Atho’illah, M. F., Rifa’i, M., Widodo, N., & Djati, M. S. (2021) · Journal of Pharmacy & Pharmacognosy Research · doi:10.56499/jppres21.1092_9.6.824 · Cited by 29
Iron‐Sulfur Clusters: A Key Factor of Regulated Cell Death in Cancer
Zhang, M., Liu, Z., Le, Y., Gu, Z., & Zhao, H. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/7449941 · Cited by 32
Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer
Shi, Y.-H., Xu, Q., Zhu, Y., Liu, Z., Zhao, G., Liu, Q., Wang, X.-Y., Wang, J., Xu, X. S., Su, Q., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.11.004 · Cited by 29
BSA-magnetite nanotorpedo for safe and efficient delivery of chemotherapy drugs
Zhao, X., Xu, S., Jiang, Y. Q., Wang, C., Rehman, S. U., Ji, S., Wang, J., Tao, T., Xu, H., Chen, R., et al. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.140440 · Cited by 28
The hypoxia-inducible factor-1α in stemness and resistance to chemotherapy in gastric cancer: Future directions for therapeutic targeting
Özcan, G. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1082057 · Cited by 31
A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy
Kumar, P., Mangla, B., Javed, S., Ahsan, W., Musyuni, P., Sivadasan, D., Alqahtani, S. S., & Aggarwal, G. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1149554 · Cited by 29
The interactions between DNA methylation machinery and long non-coding RNAs in tumor progression and drug resistance
Al-Imam, M. J., Hussein, U. A., Sead, F. F., Faqri, A. M. A., Mekkey, S. M., khazel, A. J., & Almashhadani, H. A. (2023) · DNA repair · doi:10.1016/j.dnarep.2023.103526 · Cited by 29
Therapeutic targeting of ATR in alveolar rhabdomyosarcoma
García, H. D., Pusch, F. F., Bei, Y., von Stebut, J., Ibáñez, G., Guillan, K. C., Imami, K., Gürgen, D., Rolff, J., Helmsauer, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32023-7 · Cited by 29
Advances in Nanodelivery Systems Based on Metabolism Reprogramming Strategies for Enhanced Tumor Therapy.
Zhang, Z.-Q., Liang, X.-Y., Yang, X., Liu, Y., Zhou, X., & Li, C.-H. (2024) · ACS Applied Materials and Interfaces · doi:10.1021/acsami.3c15686 · Cited by 26
Nanozymes in cancer immunotherapy: metabolic disruption and therapeutic synergy
Xu, X., Zhang, Y., Meng, C., Zheng, W., Wang, L., Zhao, C., & Luo, F. (2024) · Journal of Materials Chemistry B · doi:10.1039/d4tb00769g · Cited by 28
Long non-coding RNA-based glycolysis-targeted cancer therapy: feasibility, progression and limitations
Liu, R., Wang, X., Shen, Y., & He, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06247-7 · Cited by 28
Molecular Hydrogen as a Novel Antitumor Agent: Possible Mechanisms Underlying Gene Expression
Hirano, S., Yamamoto, H., Ichikawa, Y., Sato, B., Takefuji, Y., & Satoh, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168724 · Cited by 29
Dark Side of Cancer Therapy: Cancer Treatment-Induced Cardiopulmonary Inflammation, Fibrosis, and Immune Modulation
Boopathi, E., & Thangavel, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810126 · Cited by 29
LRGCPND: Predicting Associations between ncRNA and Drug Resistance via Linear Residual Graph Convolution
Li, Y., Wang, R., Zhang, S., Xu, H., & Deng, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910508 · Cited by 29
CircRNA_0044556 diminishes the sensitivity of triple‑negative breast cancer cells to adriamycin by sponging miR‑145 and regulating NRAS
Chen, J., Shi, P., Zhang, J., Li, Y., Ma, J., Zhang, Y., & Liu, H. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12567 · Cited by 28
Potentials of Endophytic Fungi in the Biosynthesis of Versatile Secondary Metabolites and Enzymes
Slama, H. B., Bouket, A. C., Alenezi, F. N., Pourhassan, Z., Golińska, P., Oszako, T., & Belbahri, L. (2021) · Forests · doi:10.3390/f12121784 · Cited by 28
Mesenchymal Stem Cell-Derived Extracellular Vesicles: Pleiotropic Impacts on Breast Cancer Occurrence, Development, and Therapy
Guo, Y., Zhai, Y., Wu, L., Wang, Y., Wu, P., & Xiong, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062927 · Cited by 28
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
Calabrese, F., Pezzuto, F., Lunardi, F., Fortarezza, F., Tzorakoleftheraki, S., Resi, M. V., Tinè, M., Pasello, G., & Hofman, P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084164 · Cited by 28
Activation of the integrated stress response is a vulnerability for multidrug‐resistant FBXW7‐deficient cells
Sanchez‐Burgos, L., Navarro‐González, B., García‐Martín, S., Sirozh, O., Mota‐Pino, J., Fueyo‐Marcos, E., Tejero, H., Antón, M. E., Murga, M., Al‐Shahrour, F., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202215855 · Cited by 27
In situ monitoring of functional activity of extracellular matrix stiffness-dependent multidrug resistance protein 1 using scanning electrochemical microscopy
Kuermanbayi, S., Yang, Y., Zhao, Y., Li, Y., Wang, L., Yang, J., Zhou, Y., Xu, F., & Li, F. (2022) · Chemical Science · doi:10.1039/d2sc02708a · Cited by 28
QSAR modeling and molecular docking studies of 2-oxo-1, 2-dihydroquinoline-4- carboxylic acid derivatives as p-glycoprotein inhibitors for combating cancer multidrug resistance
Lahyaoui, M., Diane, A., El-Idrissi, H., Saffaj, T., Rodi, Y. K., & Ihssane, B. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13020 · Cited by 28
Acquired Secondary HER2 Mutations Enhance HER2/MAPK Signaling and Promote Resistance to HER2 Kinase Inhibition in Breast Cancer
Marín, A., Mamun, A. A., Patel, H. M., Akamatsu, H., Ye, D., Sudhan, D. R., Eli, L. D., Marcelain, K., Brown, B. P., Meiler, J., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3617 · Cited by 30
Antiproliferative Activities and SwissADME Predictions of Physicochemical Properties of Carbonyl Group‐Modified Rotenone Analogues
Hernandez, R. D., Genio, F. A. F., Casanova, J., Conato, M. T., & Paderes, M. C. (2023) · ChemistryOpen · doi:10.1002/open.202300087 · Cited by 28
Targeting drug‐tolerant cells: A promising strategy for overcoming acquired drug resistance in cancer cells
Song, X.-H., Yang, L., Zheng, X., Zhu, Q., Liao, X.-L., Liu, K., Zhang, W., Peng, Q., Zhu, Y., Zhao, L.-Y., et al. (2023) · MedComm · doi:10.1002/mco2.342 · Cited by 28
Succinate based polymers drive immunometabolism in dendritic cells to generate cancer immunotherapy
Inamdar, S., Suresh, A. P., Mangal, J. L., Ng, N. D., Sundem, A., Behbahani, H. S., Rubino, T. E., Shi, X., Loa, S. T., Yaron, J. R., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.05.014 · Cited by 30
The biological essence of synthetic lethality: Bringing new opportunities for cancer therapy
Ge, M., Luo, J., Wu, Y., Shen, G., & Kuang, X. (2024) · MedComm – Oncology · doi:10.1002/mog2.70 · Cited by 31
Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong In Vivo Antitumor Activity
Hu, J., Xu, H., Wu, T., Zhang, C., Shen, H., Dong, R., Hu, Q., Xiang, Q., Chai, S., Luo, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02195 · Cited by 28
Mn-based Prussian blue analogues: Multifunctional nanozymes for hydrogen peroxide detection and photothermal therapy of tumors
Liu, J., Zhang, X., Zhang, Y., Zhao, B., Liu, Z., Dong, X., Feng, S., & Du, Y. (2024) · Talanta · doi:10.1016/j.talanta.2024.126320 · Cited by 27
Mechanistic and therapeutic perspectives of miRNA-PTEN signaling axis in cancer therapy resistance
Wu, D., Huang, C., & Guan, K. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116406 · Cited by 27
Overcoming Chemoresistance in Cancer: The Promise of Crizotinib
Musa, S., Amara, N., Selawi, A., Wang, J., Marchini, C., Agbarya, A., & Mahajna, J. A. (2024) · Cancers · doi:10.3390/cancers16132479 · Cited by 27
Metallodrugs: Synthesis, mechanism of action and nanoencapsulation for targeted chemotherapy
Rodrigues, J. A. O., Kiran, N. S., Chatterjee, A., Prajapati, B. G., Dhas, N. L., dos Santos, A. O., de Sousa, F. F., & Souto, E. B. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116644 · Cited by 31
CHMP4C promotes pancreatic cancer progression by inhibiting necroptosis via the RIPK1/RIPK3/MLKL pathway
Yu, L., Guo, Q., Li, Y., Mao, M., Liu, Z., Li, T., Wang, L., & Zhang, X. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.01.040 · Cited by 27
A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths
Zhu, G., Rahman, C. R., Getty, V., Odinokov, D., Baruah, P., Carrié, H., Lim, A. J., Guo, Y. A., Poh, Z. W., Sim, N. L., et al. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01370-3 · Cited by 27
Coptidis rhizoma and berberine as anti-cancer drugs: A 10-year updates and future perspectives
Chen, G., Zhang, C., Zou, J., Zhou, Z., Zhang, J., Yan, Y., Liang, Y., Tang, G., Chen, G., Xu, X., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107742 · Cited by 27
Engineered plant extracellular vesicles: Emerging nanoplatforms for combinational cancer immunotherapy
Chen, F., Bao, R., Yang, W., Lu, Y., Guo, J., Chen, W., Li, J., Feng, K., Zhang, W., Di, L., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.020 · Cited by 30
Notch signaling in female cancers: a multifaceted node to overcome drug resistance
Giuli, M. V., Mancusi, A., Giuliani, E., Screpanti, I., & Checquolo, S. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.53 · Cited by 29
A comparative study of the effects of crab derived exosomes and doxorubicin in 2 & 3-dimensional in vivo models of breast cancer
Rezakhani, L., Rahmati, S., Ghasemi, S., Alizadeh, M., & Alizadeh, A. (2022) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2022.105179 · Cited by 27
Integrated Design of a Membrane‐Lytic Peptide‐Based Intravenous Nanotherapeutic Suppresses Triple‐Negative Breast Cancer
Chen, C. H., Liu, Y., Eskandari, A., Ghimire, J., Lin, L. C. W., Fang, Z., Wimley, W. C., Ulmschneider, J. P., Suntharalingam, K., Hu, C. J., et al. (2022) · Advanced Science · doi:10.1002/advs.202105506 · Cited by 27
Role of the Wnt and GTPase pathways in breast cancer tumorigenesis and treatment
Ebrahimi, N., Kharazmi, K., Ghanaatian, M., Miraghel, S. A., Amiri, Y., Seyedebrahimi, S. S., Mobarak, H., Yazdani, E., Parkhideh, S., Hamblin, M. R., et al. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.05.001 · Cited by 26
Therapeutic Potential for Targeting Autophagy in ER+ Breast Cancer
Finnegan, R., Elshazly, A. M., Schoenlein, P. V., & Gewirtz, D. A. (2022) · Cancers · doi:10.3390/cancers14174289 · Cited by 27
Therapeutic Efficacy of Benzimidazole and Its Analogs: An Update
Basha, N. J. (2022) · Polycyclic aromatic compounds · doi:10.1080/10406638.2022.2118334 · Cited by 27
When cancer drug resistance meets metabolomics (bulk, single-cell and/or spatial): Progress, potential, and perspective
Zhang, Z., Bao, C., Jiang, L., Wang, S., Wang, K., Lu, C., & Fang, H. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2022.1054233 · Cited by 30
Selective Eradication of Colon Cancer Cells Harboring PI3K and/or MAPK Pathway Mutations in 3D Culture by Combined PI3K/AKT/mTOR Pathway and MEK Inhibition
Atanasova, V. S., Riedl, A., Strobl, M. M., Flandorfer, J., Unterleuthner, D., Weindorfer, C., Neuhold, P., Stang, S., Hengstschläger, M., Bergmann, M. M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021668 · Cited by 27
Effects of Nitro-Oxidative Stress on Biomolecules: Part 1—Non-Reactive Molecular Dynamics Simulations
Ghasemitarei, M., Ghorbi, T., Yusupov, M., Zhang, Y. T., Zhao, T., Shali, P., & Bogaerts, A. (2023) · Biomolecules · doi:10.3390/biom13091371 · Cited by 26
Gene regulatory network topology governs resistance and treatment escape in glioma stem-like cells
Park, J. H., Hothi, P., de Lomana, A. L. G., Pan, M., Calder, R., Turkarslan, S., Wu, W., Lee, H., Patel, A. P., Cobbs, C., et al. (2024) · Science Advances · doi:10.1126/sciadv.adj7706 · Cited by 25
Indole Compounds in Oncology: Therapeutic Potential and Mechanistic Insights
HASSAN, S. M. E., Farid, A., Panda, S. S., Bekheit, M. S., Dinkins, H., Fayad, W., & Girgis, A. S. (2024) · Pharmaceuticals · doi:10.3390/ph17070922 · Cited by 26
RNA ac4C modification in cancer: Unraveling multifaceted roles and promising therapeutic horizons
Ouyang, W., Huang, Z., Wan, K., Nie, T., Chen, H., & Yao, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217159 · Cited by 26
Multifunctional nanodrug for simultaneously combating chemoresistance and immunosuppression in Fusobacterium nucleatum-associated colorectal cancer
Li, X., Wu, M., Wu, Y. C., Xin, Y., Gao, L., Elsabahy, M., Wang, X., Zhang, J., Qu, X., & Gao, H. (2025) · Acta Biomaterialia · doi:10.1016/j.actbio.2025.02.013 · Cited by 26
Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment
Liu, R., Wang, C., Tao, Z., & Hu, G. (2025) · Biomedicines · doi:10.3390/biomedicines13081895 · Cited by 28
Adaptive changes induced by noble-metal nanostructures in vitro and in vivo
Huang, Q., Zhang, J., Zhang, Y., Timashev, P. S., Ma, X., & Liang, X. (2020) · Theranostics · doi:10.7150/thno.42569 · Cited by 26
Human cancer germline antigen-specific cytotoxic T cell—what can we learn from patient
Hamid, M. A., Peng, Y., & Dong, T. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0468-x · Cited by 27
Reducing Doxorubicin resistance in breast cancer by liposomal FOXM1 aptamer: In vitro and in vivo
Ghandhariyoun, N., Jaafari, M. R., Nikoofal‐Sahlabadi, S., Taghdisi, S. M., & Moosavian, S. A. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118520 · Cited by 26
Targeting glyco-immune checkpoints for cancer therapy
Manni, M., & Laubli, H. P. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1882989 · Cited by 26
Mn(II) catalyzed synthesis of 5(4-hydroxyphenyl)-2-(N-phenylamino)-1,3,4-oxadiazole: Crystal structure, DFT, molecular docking, Hirshfeld surface analysis, and in vitro anticancer activity on DL cells
Gond, M. K., Shukla, A., Pandey, S. K., Bharty, M. K., Maiti, B., Acharya, A., Tiwari, N., Katiyar, D., & Butcher, R. J. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131547 · Cited by 26
Combination of a STAT3 inhibitor with anti-PD-1 immunotherapy is an effective treatment regimen for a vemurafenib-resistant melanoma
Kim, T. W., Kim, Y., Keum, H., Jung, W., Kang, M., & Jon, S. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.06.001 · Cited by 26
Development of new bioactive molecules to treat breast and lung cancer with natural myricetin and its derivatives: A computational and SAR approach
Akash, S., Kumer, A., Rahman, M. M., Emran, T. B., Sharma, R., Singla, R. K., Alhumaydhi, F. A., Khandaker, M. U., Park, M. N., Idris, A. M., et al. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.952297 · Cited by 26
Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer
Zhou, M., Lv, S., Hou, Y., Zhang, R., Wang, W., Yan, Z., Li, T., Gan, W., Zeng, Z., Zhang, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.994874 · Cited by 24
First-in-Class Dual Mechanism Ferroptosis-HDAC Inhibitor Hybrids
Karaj, E., Sindi, S. H., Kuganesan, N., Koranne, R., Knoff, J. R., James, A. W., Fu, Y., Kotsull, L. N., Pflum, M. K. H., Shah, Z. A., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01276 · Cited by 27
Dual-Channel Heterogeneous Graph Neural Network for Predicting microRNA-Mediated Drug Sensitivity
Deng, L., Fan, Z., Xiao, X., Liu, H., & Zhang, J. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01060 · Cited by 26
Reshaping the tumor microenvironment: extracellular vesicles as messengers of cancer cells
Bhatta, B., & Cooks, T. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa107 · Cited by 27
Antitumor Activity of Pulvomycin via Targeting Activated-STAT3 Signaling in Docetaxel-Resistant Triple-Negative Breast Cancer Cells
Byun, W. S., Bae, E. S., Cui, J., Park, H. J., Oh, D., & Lee, S. K. (2021) · Biomedicines · doi:10.3390/biomedicines9040436 · Cited by 26
Epigenetic deregulation in breast cancer microenvironment: Implications for tumor progression and therapeutic strategies
Trnkova, L., Buociková, V., Mego, M., Čumová, A., Buríková, M., Boháč, M., Miklikova, S., Cihova, M., & Smolková, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116559 · Cited by 29
Electrospun nanofibers-derived functional scaffolds for cancer therapy
Kuang, G., Lin, X., Li, J., Sun, W., Zhang, Q., & Zhao, Y. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.151253 · Cited by 26
Two-Photon Photodegradation of E3 Ubiquitin Ligase Cereblon by a Ru(II) Complex: Inducing Ferroptosis in Cisplatin-Resistant Tumor Cells
Lin, X., Zheng, M., Xiong, K., Wang, F., Chen, Y., Ji, L., & Chao, H. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00545 · Cited by 25
The Role of αvβ3 Integrin in Cancer Therapy Resistance
Pachane, B. C., & Selistre-de-Araújo, H. S. (2024) · Biomedicines · doi:10.3390/biomedicines12061163 · Cited by 25
Resistance to 5-fluorouracil: The molecular mechanisms of development in colon cancer cells
Radenković, N., Nikodijević, D. D., Jovankić, J. V., Blagojević, S., & Milutinović, M. G. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176979 · Cited by 26
Lazertinib: breaking the mold of third-generation EGFR inhibitors
Patel, K. B., & Heppner, D. E. (2025) · RSC Medicinal Chemistry · doi:10.1039/d4md00800f · Cited by 26
Synthesis, cytotoxicity, antiproliferative, antioxidant, anti-inflammatory, and anti-metastatic activities of novel 2-arylidene-indane-1,3-dione scaffolds incorporating 2-phenoxy-N-arylacetamide moiety: Induction of apoptosis in Hela cells
Ibrahim, N. S., Elghany, R. A. A., Sharaky, M. M., Diab, H. M., Abdelhamid, I. A., & Elwahy, A. H. M. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.141424 · Cited by 25
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 29
Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology
Gümüşay, Ö., Vitiello, P. P., Wabl, C. A., Corcoran, R. B., Bardelli, A., & Rugo, H. S. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280845 · Cited by 29
Biomimetic nanomedicine toward personalized disease theranostics
Hao, H., Chen, Y., & Wu, M. (2020) · Nano Research · doi:10.1007/s12274-020-3265-z · Cited by 24
Morphodynamic signatures of MDA-MB-231 single cells and cell doublets undergoing invasion in confined microenvironments
Zhang, X., Chan, T., & Mak, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-85640-5 · Cited by 25
Amberlyst-15 catalysed sonochemical synthesis of 2-amino-4,6-disubstituted nicotinonitrile derivatives and their biological evaluation
Challa, C. S., Katari, N. K., Nallanchakravarthula, V., Nayakanti, D., Kapavarapu, R., & Pal, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130541 · Cited by 25
Small-Molecule Inhibitors and Degraders Targeting KRAS-Driven Cancers
Hyun, S., & Shin, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212142 · Cited by 26
Carbon Nanotubes in Tumor-Targeted Chemotherapeutic Formulations: A Review of Opportunities and Challenges
Contreras‐Torres, F. F., Treviño, D. S., Soto‐Domínguez, A., & García‐Rivas, G. (2022) · ACS Applied Nano Materials · doi:10.1021/acsanm.2c01118 · Cited by 26
Cancer plasticity: Investigating the causes for this agility
Saha, S., Pradhan, N., Neha, B., Mahadevappa, R., Minocha, S., & Kumar, S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.12.005 · Cited by 27
GH and IGF1 in cancer therapy resistance
Basu, R., & Kopchick, J. J. (2023) · Endocrine Related Cancer · doi:10.1530/erc-22-0414 · Cited by 25
The interplay between noncoding RNAs and drug resistance in hepatocellular carcinoma: the big impact of little things
Fang, Y., Zhang, X., Huang, H., & Zeng, Z. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04238-9 · Cited by 25
Steering and controlling evolution — from bioengineering to fighting pathogens
Lässig, M., Mustonen, V., & Nourmohammad, A. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00623-8 · Cited by 24
Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation
Ashrafizadeh, M., Zhang, W., Tian, Y., Sethi, G., Zhang, X., & qiu, A. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10168-9 · Cited by 25
Prospects of molecular hydrogen in cancer prevention and treatment
Zhou, W., Zhang, J., Chen, W., & Miao, C. (2024) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-024-05685-7 · Cited by 25
Ginsenoside RK3 inhibits glioblastoma by modulating macrophage M2 polarization via the PPARG/CCL2 axis
Zhang, H., Hu, J., Zhao, X., Zheng, B., Han, Y., Luo, G., & Dou, D. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.156271 · Cited by 24
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25
Exosome-Mediated Chemoresistance in Cancers: Mechanisms, Therapeutic Implications, and Future Directions
Liu, G., Liu, J., Li, S., Zhang, Y., & Ren, H. (2025) · Biomolecules · doi:10.3390/biom15050685 · Cited by 27
The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations
Esfahani, M. A., Servatian, N., Al-Athari, A. J. H., Khafaja, E. S. M., Seraji, H. R., & Samarkhazan, H. S. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01783-z · Cited by 24
The multifaceted contributions of cancer-associated fibroblasts to drug resistance in primary and metastatic tumors
Zhang, X., Wang, Y., Cui, W., Li, D., Song, J., Liu, Y., Liu, Y., & Yang, S. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101273 · Cited by 26
Drug Repositioning for P-Glycoprotein Mediated Co-Expression Networks in Colorectal Cancer
Beklen, H., Gülfidan, G., Arğa, K. Y., Mardinoğlu, A., & Turanlı, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01273 · Cited by 25

Authors: Vasan, N., Baselga, J., & Hyman, D. M.
Affiliations: Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Hyman, David M.
ORCID: Vasan, Neil
Hyman, David M.
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2019-11-13
Volume: 575
Issue: 7782
Pages: 299-309
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-019-1730-1
PMC: PMC8008476
OpenAlex: W2988773550
Cited by: 2,770
References: 188
Citations by year: 2026: 344 · 2025: 533 · 2024: 524 · 2023: 467 · 2022: 397 · 2021: 346 · 2020: 150 · 2019: 4
FWCI: 21.44
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
Funders: Eli Lilly and Company
National Cancer Institute (R01CA207244, R01CA190642, P30CA008748, T32CA009207)
Topics: Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: chemoresistance, tumor heterogeneity, tumor microenvironment, tumor immune evasion, tumor growth kinetics, tumor burden, early cancer detection, adaptive monitoring, synthetic lethality screen, precision oncology
MeSH terms: Antineoplastic Agents, Humans, Models, Biological, Neoplasms, Drug Resistance, Neoplasm, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A view on drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks